Cutia Therapeutics (2487.HK)

5,900 +0,200 (+3,51 %) À la clôture : 04:08PM HKT

Cutia Therapeutics

Huanzhi Building
20th Floor 436 Heng Feng Road Jingan District
Shanghai 200070
China
86 21 5298 2688
https://www.cutiatx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 298

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Ms. Lele Zhang	Founder, CEO & Executive Director	4,55M	S.O.	1977
Mr. Yuqing Huang	CFO & Executive Director	7,67M	S.O.	1990
Mr. Qi Zhu	Chief Medical Officer	S.O.	S.O.	1973
Dr. Lei Lei	Senior Vice President of Research & Development Department	S.O.	S.O.	1985
Ms. Chunna Zhang	Senior Vice President of Regulatory Affairs Department	S.O.	S.O.	1979
Ms. Jingxin Xu	Senior Vice President of Manufacturing & Quality Control Department	S.O.	S.O.	1979
Mr. Jiaru Wu	Senior Vice President of Finance & Integrated Management Department	S.O.	S.O.	1984
Ms. Sze Ting Chan A.C.S.	Company Secretary	S.O.	S.O.	1982

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en HKD.

Description

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company's products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment; CU-10201, a topical 4% minocycline foam, approved for acne vulgaris treatment; and CU-10101, a topical novel small molecule agent, and a non-hormonal and small molecule drug for the treatment of mild to moderate atopic dermatitis. It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations. The company was incorporated in 2019 and is headquartered in Shanghai, China.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Cutia Therapeutics en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.